CSL : Seqirus' $800m+ innovative vaccine and antivenom manufacturing facility in Australia reaches major construction milestone
CSL Seqirus $800m+ innovative vaccine and antivenom manufacturing facility in Australia reaches major construction milestone Melbourne,... | May 21, 2023
Source: marketscreener.com